Literature DB >> 9167542

The panic-agoraphobic spectrum: a descriptive approach to the assessment and treatment of subtle symptoms.

G B Cassano1, S Michelini, M K Shear, E Coli, J D Maser, E Frank.   

Abstract

OBJECTIVE: Psychiatric classification is still a topic of considerable discussion and debate in spite of major advances in the past two decades. The debate involves categorical versus dimensional approaches, cutoff numbers of symptoms to define a case, degree of impairment, objective diagnostic criteria versus more theoretically based criteria, episodic versus trait-like symptoms, and the role of atypical and subclinical symptoms. All of these issues have been raised for the anxiety disorders and depression. This article presents the conceptualization of a relatively novel and testable approach to the diagnosis and classification of panic and agoraphobia, the panic-agoraphobic spectrum, and pilot data on a new questionnaire to assess it.
METHOD: Pilot testing of the Panic-Agoraphobic Spectrum Questionnaire was undertaken with 100 inpatients who had lifetime diagnoses of panic disorder, unipolar depression, comorbid panic and unipolar depressive disorders, or an eating disorder. The instrument emphasizes impairment related to 144 behaviors and experiences in seven panic-agoraphobic symptom domains.
RESULTS: Patients with panic disorder scored highest on the questionnaire, and those with comorbid depression showed even greater severity of illness. The scores of the patients with eating disorders and of the depressed patients differed from those of the other groups but also differed from 0.
CONCLUSIONS: The spectrum model of panic and agoraphobia is a flexible and comprehensive means of describing this clinical complex. The proposed model, complementary to the categorical approach, presumably expresses a unitary pathophysiology. Its usefulness is discussed in terms of its value for patient-therapist communication, outcome measures, identification of subtle personality traits, and subtyping of patients for research and treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9167542     DOI: 10.1176/ajp.154.6.27

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  24 in total

Review 1.  Construct models in veterinary behavioural medicine: lessons from the human experience.

Authors:  G Sheppard; D S Mills
Journal:  Vet Res Commun       Date:  2003-04       Impact factor: 2.459

2.  Caffeine consumption among eating disorder patients: epidemiology, motivations, and potential of abuse.

Authors:  A Burgalassi; C E Ramacciotti; M Bianchi; E Coli; L Polese; E Bondi; G Massimetti; L Dell'osso
Journal:  Eat Weight Disord       Date:  2009-12       Impact factor: 4.652

3.  Personality disorder traits as predictors of subsequent first-onset panic disorder or agoraphobia.

Authors:  O Joseph Bienvenu; Murray B Stein; Jack F Samuels; Chiadi U Onyike; William W Eaton; Gerald Nestadt
Journal:  Compr Psychiatry       Date:  2008-10-21       Impact factor: 3.735

4.  The impact of panic-agoraphobic comorbidity on suicidality in hospitalized patients with major depression.

Authors:  Lily A Brown; Brandon A Gaudiano; Ivan W Miller
Journal:  Depress Anxiety       Date:  2010-03       Impact factor: 6.505

5.  Best Design for Multidimensional Computerized Adaptive Testing With the Bifactor Model.

Authors:  Dong Gi Seo; David J Weiss
Journal:  Educ Psychol Meas       Date:  2015-03-25       Impact factor: 2.821

6.  Predictors and moderators of time to remission of major depression with interpersonal psychotherapy and SSRI pharmacotherapy.

Authors:  E Frank; G B Cassano; P Rucci; W K Thompson; H C Kraemer; A Fagiolini; L Maggi; D J Kupfer; M K Shear; P R Houck; S Calugi; V J Grochocinski; P Scocco; J Buttenfield; R N Forgione
Journal:  Psychol Med       Date:  2010-04-12       Impact factor: 7.723

7.  Therapist Use of Specific and Nonspecific Strategies Across Two Affect-Focused Psychotherapies for Depression: Role of Adherence Monitoring.

Authors:  Marlissa C Amole; Jill M Cyranowski; Laren R Conklin; John C Markowitz; Stacy E Martin; Holly A Swartz
Journal:  J Psychother Integr       Date:  2016-06-06

8.  Treating co-occurring depression and anxiety: modeling the dynamics of psychopathology and psychotherapy using the time-varying effect model.

Authors:  Aidan G C Wright; Michael N Hallquist; Holly A Swartz; Ellen Frank; Jill M Cyranowski
Journal:  J Consult Clin Psychol       Date:  2013-09-16

9.  Acceptability, validity and reliability of the Structured Clinical Interview for the Spectrum of Substance Use (SCI-SUBS): a pilot study.

Authors:  A Sbrana; L Dell'Osso; C Gonnelli; P Impagnatiello; M R Doria; S Spagnolli; L Ravani; G B Cassano; E Frank; M K Shear; V J Grochocinski; P Rucci; J D Maser; J Endicott
Journal:  Int J Methods Psychiatr Res       Date:  2003       Impact factor: 4.035

10.  Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression.

Authors:  Jean-Philippe Guilloux; Sabrina Bassi; Ying Ding; Chris Walsh; Gustavo Turecki; George Tseng; Jill M Cyranowski; Etienne Sibille
Journal:  Neuropsychopharmacology       Date:  2014-09-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.